Vyxeos liposomal 44 mg/100 mg
As listed in the register: Vyxeos liposomal 44 mg/100 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionsdispersion
44 mg + 100 mg ·
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Cytarabinum + Daunorubicinum
- Made by
- Jazz Pharmaceuticals Switzerland GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Vyxeos liposomal ist indiziert zur Behandlung von Erwachsenen mit neu diagnostizierter, therapieassoziierter akuter myeloischer Leukämie (t-AML) oder AML mit Myelodysplasie-assoziierten Veränderungen (AML-MRC).
From the official label · 2026-09-30 · Swissmedic
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Jazz Pharmaceuticals Switzerland GmbH |
|---|---|
| Active substance | Cytarabinum + Daunorubicinum |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 44 mg + 100 mg |
| Classification | L01XY01 · Cancer treatments and immune-system medicines |
| Dispensing (as stated by the register) | Abgabekategorie A |
| Name in the register | Vyxeos liposomal 44 mg/100 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionsdispersion |
| Packs | 1 Durchstechflasche(n) · 2 Durchstechflasche(n) · 5 Durchstechflasche(n) |
| Zulassungsnummer | 68014 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.